Non-small cell lung cancer+5
Not recruitingStudy of sacituzumab govitecan and zimberelimab treatment before and after surgery for patients with resectable non-small cell lung cancer
Study of sacituzumab govitecan and zimberelimab treatment before and after surgery for patients with resectable non-small cell lung cancer
- Disease:Non-small cell lung cancerNon-small cell lung cancer stage III+4
- Substances:ZimberelimabSacituzumab Govitecan
Germany- Participants:18–64 years · 65+ years
- Substances:Zimberelimab
- Sponsor:AIO-Studien gGmbH











